ReceptIVFity is able to successfully predict embryo implantation failure before the initiation of a fertility treatment cycle such as In Vitro Fertilization (IVF) and/or Intra-cytoplasmic sperm injection (ICSI). ReceptIVFity is based on the application of proprietary algorithms and patented bacterial biomarker profiles of the urogenital tract. This is also known as Fertility Microbiome Profiling,
During the ReceptIVFity-I trial, the results of earlier single-center clinical studies have been validated in a multicenter setting. For this study 300 patients were included originating from 8 Dutch IVF clinics. A secondary purpose of the ReceptIVFity-I trial design was to technically validate different high-throughput platform technologies. These technologies support personalized, quick, robust and sensitive predictions. The outcome of the ReceptIVFity-I trial clearly demonstrates the capacities of the urogenital microbiome composition as a predictor for pregnancy outcome after IVF/ICSI.
For the development of the commercial version of ReceptIVFity, top scientists have been involved to help select the most optimal urogenital sampling sites and sampling procedures, and the advice on the most suitable technology for high-throughput analyses. Furthermore the research team has optimized the predictive algorithm and personalized information sheet that will accompany each analysis. Currently, the investigating team will strategically merge the validation of the assay and algorithm with building a dossier for CE certification. Clinical validation in this project will involve several top IVF centers in Europe.
For more information about the ReceptIVFity trials go to: www.ReceptIVFity.com